Perusicová J
Diabetologické centrum Interní kliniky 2. lékarské fakulty UK a FN Motol Praha.
Vnitr Lek. 2007 Oct;53(10):1109-13.
Sitagliptin, distributed under the brand name of Januvia, has been the first and so far the only dipeptidyl peptidase IV (DPP-IV) inhibitor introduced in clinical practice. The results of published clinical studies clearly demonstrate its effectiveness and safety as an oral antidiabetic. Apart from increasing the insulin level, Sitagliptin reduces the level ofglucagon. The principal advantages of Sitagliptin from the clinical point of view are: a) the ability to reduce both fasting and non-fasting glycaemia and improve the HbA(1c) values, b) the fact that it does not provoke weight increase, c) the fact that the risk of hypoglycaemia is significantly lower as compared with sulfonylurea derivatives, d) good tolerability.
西格列汀，商品名为佳维乐，是首个且迄今为止唯一被引入临床实践的二肽基肽酶IV（DPP-IV）抑制剂。已发表的临床研究结果清楚地证明了其作为口服抗糖尿病药物的有效性和安全性。除了提高胰岛素水平外，西格列汀还能降低胰高血糖素水平。从临床角度来看，西格列汀的主要优点包括：a）能够降低空腹和非空腹血糖水平并改善糖化血红蛋白（HbA1c）值；b）不会引起体重增加；c）与磺脲类衍生物相比，低血糖风险显著更低；d）耐受性良好。
